Articles tagged with Brain Cancer
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
A new molecule called the 'Fusion Superkine' has been created to target and kill glioblastoma cells while stimulating an immune response to prevent recurrence. The treatment, developed by VCU Massey Comprehensive Cancer Center researchers, uses a combination of immunotherapy and targeted delivery to overcome the blood-brain barrier and...
Researchers at the University of Missouri have developed a new imaging probe that can help surgeons accurately identify and remove aggressive brain tumors during operations. The tool, known as FA-ICG, uses near-infrared light to highlight tumor cells from within.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers found that using Tumor Treating Fields therapy (TTFields) combined with immunotherapy (pembrolizumab) and chemotherapy (temozolomide) may extend survival for glioblastoma patients. TTFields disrupt tumor growth, attracting more immune cells to attack cancerous cells.
Researchers at Virginia Tech's Fralin Biomedical Research Institute are developing more precise treatments for pediatric brain cancer, specifically glioblastoma, by targeting cancer cells while sparing healthy tissue. The new therapies aim to deliver compounds more effectively to tumor sites using low-intensity focused ultrasound.
A phase I clinical trial demonstrates that dual-target CAR T cell therapy can reduce tumor size in nearly two-thirds of patients with recurrent glioblastoma, a notoriously aggressive brain cancer. The therapy also shows signs of long-term immune system activation and potential for extended tumor stability.
Scientists at Terasaki Institute engineer a novel 3D glioblastoma model that mimics brain tissue and pericyte role, showing increased resistance to chemotherapy. The model increases sensitivity of GBM cell lines to TMZ by 22-32%.
The University of Houston has launched a $3M Cancer Immunotherapy Biomarker Core to accelerate early diagnosis and treatment response in cancer. The core will offer comprehensive targeted proteomic cancer biomarker screens, enabling researchers to identify better biomarkers for cancer.
Researchers at Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard uncovered critical insights into the biology of embryonal tumor with multilayered rosettes (ETMR), a rare and aggressive brain tumor affecting young children. Targeting FGFR and NOTCH receptors may represent a critical vulnerability in ETMR.
A rare form of childhood brain cancer called Diffuse Midline Glioma (DMG) hijacks gene control machinery to fuel its growth. A specific gene-silencing complex, CBX4/PCGF4-cPRC1, is essential for tumour growth and could be a promising drug target.
A new ultra-rapid genetic test has been developed to diagnose brain tumors in under two hours, cutting the current wait time of 6-8 weeks. The test uses Oxford Nanopore Technologies portable sequencing devices and achieves a 100% success rate.
A new protein target has been identified for treating childhood medulloblastomas. High levels of dihydrolipoyl transacetylase make Group-3 medulloblastomas vulnerable to cuproptosis, a newly discovered form of copper-dependent cell death.
A new study uses explainable machine learning to predict metastasis and mortality in children with medulloblastoma, identifying key immune factors driving risk. The model provides a transparent approach to prognostic accuracy and supports personalized clinical decision-making.
Researchers have developed a new compound, SHP1705, that selectively attacks glioblastoma stem cells by hijacked circadian clock proteins. The compound was found to be safe and well-tolerated in humans during a phase 1 clinical trial.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
Researchers investigated the clinical outcomes of concurrent TTFields therapy with CRT in patients with newly diagnosed glioblastoma, finding no significant difference in survival outcomes compared to adjuvant therapy. The study also showed comparable safety profiles for both treatment groups.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
University of Oklahoma researchers discovered ZIP4 protein drives glioblastoma progression through extracellular vesicles and reprogrammed microglial plasticity. The study identifies ZIP4 and TREM1 as promising therapeutic targets for treating aggressive brain cancer.
A new AI tool has been developed to predict the relapse of pediatric brain cancer with high accuracy, using temporal learning algorithms to analyze sequential brain scans. The tool achieved an accuracy of 75-89% in predicting recurrence, outperforming predictions based on single images.
A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.
Researchers at Dana-Farber Cancer Institute have identified a potential targeted therapy, avapritinib, for pediatric high-grade gliomas. The treatment resulted in tumor reduction and clinical improvement in 3 out of 7 patients with this currently incurable form of brain cancer.
Researchers developed a new diagnostic platform that classifies brain tumors based on the body's cancer-fighting immune response. The approach tailors treatment options to each patient's unique immune profile, offering improved diagnostics and potential for immunotherapies to revolutionize childhood leukemia treatments.
Researchers identified PDGFRA as a promising therapeutic target for pediatric high-grade gliomas. Inhibition of the PDGFRA signaling pathway leads to tumor cell death and has shown potential in laboratory and animal models, as well as initial clinical experience with avapritinib therapy.
Researchers at Broad Institute of MIT and Harvard have identified four coordinated gene expression programs in immune cells from glioma tumors that can lead to immunotherapy resistance. The study found two programs that could be targeted to improve patient response to immunotherapies, including one that may reduce the effectiveness of ...
A new study finds that dexamethasone, a commonly prescribed anti-swelling drug, can significantly reduce the body's immune response to brain cancer for weeks after its last dose. This effect is stronger with higher dosages and may impact immunotherapy treatments.
Researchers at Tel Aviv University have developed a novel method to measure PTEN gene activity, which is associated with cancer and autism. This breakthrough may lead to personalized therapeutics and earlier disease detection.
Researchers developed Ultra-Rapid droplet digital PCR to quickly identify genetic mutations in brain tumors, enabling accurate removal during surgery. The tool can detect small numbers of cancer cells and has the potential to become a practical tool for real-time detection during brain surgery.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
Researchers found a biomarker, RNA Polymerase II (RNAPII), associated with tumor aggressiveness and recurrence in meningioma and breast cancers. The study developed a novel profiling technology, Cleavage Under Targeted Accessible Chromatin (CUTAC), to measure gene transcription activity from DNA, which predicted cancer outcomes.
Researchers at Rice University's Synthesis X Center and MD Anderson Cancer Center are developing a light-induced brain delivery platform to improve drug delivery across the blood-brain barrier for treating brain metastasis. The goal is to enhance survival rates and transform the standard of care for this deadly form of cancer.
Researchers developed an AI model to detect brain cancer spread in surrounding tissue using MRI scans, showing 85-per-cent accuracy. This non-surgical method offers insights into patients' cancer without aggressive surgery, potentially improving treatment and survival.
Researchers from the Keck School of Medicine of USC found an association between levels of manmade “forever chemicals” in drinking water and certain digestive, endocrine, respiratory, and mouth and throat cancers. The study estimated that PFAS contamination contributes to 6,864 cancer cases per year.
The study identified a modified imaging approach and volumetric measurements as more accurate in predicting survival compared to other methods. These approaches worked well even for small tumors, suggesting they should be included in future studies.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.
Researchers used lab-grown organoids from glioblastoma tumors to model patient response to CAR T cell therapy. The organoids accurately reflected the treatment's effect on actual tumors, providing a promising tool for personalized medicine.
Researchers at the Wistar Institute have designed a novel trispecific antibody that targets glioblastoma antigens, providing long-term survival and sustained antitumor efficacy in heterogeneous GBM challenge models. The treatment promotes antitumor cytotoxicity with patient immune cells.
Researchers have trained AI models to distinguish brain tumors from healthy tissue using convolutional neural networks and transfer learning. The models achieved an average accuracy of 85.99% at detecting brain cancer, with the ability to generate images showing specific areas in its tumor-positive or negative classification.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
In a groundbreaking trial, CAR-T cell therapy has shown promising results in shrinking brain tumors and restoring neurologic function in children with deadly brain cancer. The study found significant clinical benefits in nine out of 11 participants, including four who experienced complete tumor regression.
Researchers developed an AI-powered model called FastGlioma that can detect residual tumor tissue with high accuracy in 10 seconds. The technology outperformed conventional methods, reducing the risk of missed tumors by nearly 75%. This innovation could change the field of neurosurgery and minimize reliance on radiographic imaging.
Scientists at WashU Medicine have successfully forced glioblastoma cells to display immune system targets, potentially making them vulnerable to immunotherapies. The strategy involves a combination of two FDA-approved epigenetic therapy drugs that induce the production of unusual proteins called neoantigens.
Children who survived childhood brain cancer are more likely to struggle academically, with a greater chance of being held back and performing poorly on state testing. The study's findings highlight the need for better support and resources to help these students succeed.
A recent clinical trial analysis found that patients with truly unmethylated MGMT promoter do not benefit from temozolomide treatment, challenging current treatment protocols. This study aims to transform the treatment landscape for older adults glioblastoma patients by identifying biomarkers for more personalized therapies.
Researchers evaluated the efficacy and safety of using Zika virus for treating CNS tumors, finding that it reduces cell viability, inhibits growth, and decreases Bcl2 expression, potentially enhancing chemotherapy and radiotherapy effects. This ultimately led to significant tumor remission and improved long-term survival through an enh...
Researchers have identified a critical genetic group that is near incurable using current therapies, leading to improved survival and quality of life for children with Group 3 medulloblastoma. The study also uncovered a potential targetable mechanism for new therapies aimed at improving outcomes.
A study by Ohio State University researchers found that combining pimozide with CB-839 can effectively suppress glioblastoma growth by blocking lipid production and starvation of tumor cells. This innovative combination may also hold promise for treating other cancers relying on glutamine and lipids.
Researchers identified AM-101 as a potential new way to enhance radiation therapy for patients with lung cancer that has spread to the brain. The drug's ability to activate GABA(A) receptors increases autophagy in lung cancer cells, making them more sensitive to radiation treatment.
Researchers at McMaster University have identified a critical vulnerability in metastatic brain cancer that can be exploited with new drugs. By targeting an enzyme called IMPDH, they anticipate preventing brain metastasis from occurring. The study has shown promising results and could lead to an alternative treatment option for patients
A pooled analysis of three large, phase III clinical trials found that more than 40% of brain metastases patients can fully reverse cognitive losses with conformal radiation techniques. Recovery was more likely for those treated with highly targeted radiation compared to standard whole-brain treatment.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
Researchers have developed a novel platform for testing radiation therapy effects on brain cells, providing insights into how the brain reacts to cancer treatment. The study aims to improve treatment strategies by understanding the impact of radiation on neural circuits, ultimately leading to personalized care for patients.
A new study reveals that a third of glioma cells, a type of brain tumor, fire electrical impulses. These hybrid cells combine features of neurons and glia, challenging the long-held notion that only neurons generate electric signals in the brain.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers at Florida State University have shown potential of a new treatment for pediatric brain cancer by enhancing natural killer immune cells to improve their ability to attack the disease. The study, published in Bioactive Materials, provides a critical part in addressing a major clinical need for children with brain cancer.
A new study finds that combining an inhibitor of a metabolic pathway with chemotherapy could improve treatment outcomes in triple negative breast cancer brain metastases. Inhibiting fatty acid synthase, an enzyme critical for cancer cell survival, shows promise in improving chemotherapy efficacy.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
Scientists have mapped over 5,000 genetic variants in the 'tumour protection' gene BAP1 that significantly increase cancer risk. These variants can be used to develop new treatments, including IGF-1 inhibitors, to slow down or prevent cancer progression.
Ternarx aims to unlock the potential of targeted protein degrader (TPD) technology to treat hard-to-treat cancers like neuroblastoma and prostate cancer. The company will initially focus on developing new treatments for these diseases using novel TPD technology.